Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Nat Rev Cancer. 2011 Jul 14;11(8):541-57. doi: 10.1038/nrc3087.
Increasingly, human mesenchymal malignancies are being classified by the abnormalities that drive their pathogenesis. Although many of these aberrations are highly prevalent within particular sarcoma subtypes, few are currently targeted therapeutically. Indeed, most subtypes of sarcoma are still treated with traditional therapeutic modalities, and in many cases sarcomas are resistant to adjuvant therapies. In this Review, we discuss the core molecular determinants of sarcomagenesis and emphasize the emerging genomic and functional genetic approaches that, coupled with novel therapeutic strategies, have the potential to transform the care of patients with sarcoma.
越来越多的人类间叶性恶性肿瘤正根据驱动其发病机制的异常情况进行分类。尽管这些异常在特定的肉瘤亚型中非常普遍，但目前很少有针对这些异常的治疗方法。事实上，大多数肉瘤亚型仍采用传统的治疗方式，而且在许多情况下，肉瘤对辅助治疗具有耐药性。在这篇综述中，我们讨论了肉瘤发生的核心分子决定因素，并强调了新兴的基因组和功能遗传学方法，这些方法与新的治疗策略相结合，有可能改变肉瘤患者的治疗方式。
